nct_id: NCT05892718
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2023-06-07'
study_start_date: '2023-10-02'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: HCB101'
long_title: A Phase 1, Open-label, Multi-center, Dose Escalation Study to Evaluate
  Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of HCB101 in Subjects
  With Advanced Solid Tumors or Relapsed and Refractory Non-Hodgkin Lymphoma
last_updated: '2025-07-01'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: NA
principal_investigator_institution: FBD Biologics Limited
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 60
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- 1. Able to understand and willing to sign the ICF.
- "2. Male and female subjects of \u226518 years of age."
- '3. Histologically/cytologically confirmed, locally advanced solid tumor: subjects
  with histologically or cytologically confirmed advanced solid tumors refractory
  to standard therapy, or for which no standard treatment exists or non-Hodgkin lymphoma,
  relapsed or refractory to at least 2 prior lines of therapy.'
- 4. For subjects with advanced solid tumor - must have at least 1 measurable lesion
  as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at baseline.
- 5. For subjects with non-Hodgkin lymphoma - must have non-Hodgkin lymphoma that
  is measurable or assessable for response per Lugano Classification (with 2016 refinement).
- 6. Must have ECOG performance status of 0 to 2 at Screening.
- 7. Able to provide tumor tissue samples.
- "8. Have life expectancy of \u226512 weeks."
- 'Exclude - Exclusion Criteria:'
- Exclude - 1. With known history of hypersensitivity to any components of HCB101.
- Exclude - 2. Known active or untreated CNS metastases and/or carcinomatous meningitis.
- Exclude - 3. Have undergone a major surgery or radical radiotherapy or palliative
  radiotherapy or have used a radioactive drug that is not completed at least 2 weeks
  prior to the first dose of HCB101.
- Exclude - 4. Clinically significant cardiovascular condition.
- "Exclude - 5. Any previous treatment-related toxicities which have not recovered\
  \ to \u2264 Grade 1 as evaluated by National Cancer Institute, Common Terminology\
  \ Criteria for Adverse Events (NCI CTCAE) version 5.0 or baseline, except alopecia\
  \ and anemia."
- Exclude - 6. With known inherited or acquired bleeding disorder or bleeding diathesis.
  .
- Exclude - 7. Have RBC transfusion within 4 weeks prior to Screening.
- Exclude - 8. With a previously documented diagnosis of hemolytic anemia or Evans
  Syndrome in the last 3 months.
- Exclude - 9. Any investigational or approved systemic cancer therapy.
- "Exclude - 10. Active use of vitamin K antagonist anticoagulant like warfarin. Use\
  \ of low molecular weight heparin and factor Xa inhibitors will be permitted on\
  \ case by case basis. There will be no restriction for daily aspirin \u2264 81 mg/QD."
- Exclude - 11. Have used herbal medication within 14 days prior to the first dose
  of HCB101.
- "Exclude - 12. Have received any treatment targeting the CD47 or SIRP\u03B1 pathway."
- Exclude - 13. Have other malignancies requiring treatment within 2 years prior to
  the first dose of HCB101.
- Exclude - 14. Participation in another clinical study with an investigational product
  administered in the last 14 days prior to receiving the first dose of HCB101.
- Exclude - 15. An investigational device used within 28 days prior to the first dose
  of HCB101.
- Exclude - 16. Positive for hepatitis B, active hepatitis C infections, positive
  for HIV, or known active or latent tuberculosis.
- Exclude - 17. Known to have a history of alcoholism or drug abuse.
short_title: "A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRP\u03B1\
  -CD47 Pathway, in Solid or Hematological Tumors"
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: FBD Biologics Limited
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: The purpose of this study is to find out whether IV injection of HCB101 is
  an effective treatment for different types of advanced solid tumors or relapsed
  and refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may
  occur in subjects aged 18 years old and above.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: HCB101
      arm_internal_id: 0
      arm_description: 'HCB101 in subjects with advanced solid tumors or relapsed
        and refractory non-Hodgkin lymphoma.


        Dosage levels: 0.08 mg/kg, 0.16 mg/kg, 0.32 mg/kg, 0.64 mg/kg, 1.28 mg/kg,
        2.56 mg/kg, and 5.12 mg/kg sequentially.'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: HCB101'
        level_internal_id: 0
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=18'
        disease_status:
        - Locally Advanced
        - Advanced
        - Recurrent
        - Refractory
        oncotree_primary_diagnosis: _SOLID_
